MIRCERA
Clinical safety rating
cautionComprehensive clinical and safety monograph for MIRCERA (MIRCERA).
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.
| Metabolism | MIRCERA is primarily eliminated via the reticuloendothelial system and not metabolized by cytochrome P450 enzymes. Minor degradation occurs via proteolysis. |
| Excretion | Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible. |
| Half-life | Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours. |
| Protein binding | Approximately 50-60% bound to serum proteins, primarily albumin, though binding is reversible and not restrictive. |
| Volume of Distribution | Approximately 3.3 L in a 70 kg patient (about 0.047 L/kg), indicating limited distribution primarily to plasma volume. This reflects the large molecular weight of the methoxy polyethylene glycol-epoetin beta conjugate, which restricts extravascular distribution. |
| Bioavailability | Subcutaneous: Approximately 62% relative to intravenous administration. Peak serum concentration occurs 72-120 hours post-dose. Absolute bioavailability not determined due to the drug's endogenous comparators. |
| Onset of Action | Subcutaneous: Increase in hemoglobin typically observed within 2-4 weeks after initiation. Intravenous: Similar onset, with reticulocyte count increases detectable within 1-2 weeks. |
| Duration of Action | Subcutaneous: Effect on hemoglobin levels persists for the entire monthly dosing interval (4 weeks). Continuous erythropoiesis stimulation is maintained with regular administration, with hemoglobin rise continuing for up to 4 weeks after a single dose in some studies. |
| Molecular Weight | 60000 |
| Action Class | Erythropoiesis-stimulating agent (ESA) |
Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/dL.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR <30 mL/min; use with caution in patients with chronic kidney disease not on dialysis; monitor hemoglobin closely. |
| Liver impairment | No specific Child-Pugh based dosing; use with caution in severe hepatic impairment; no clinical data available. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment for elderly; initial dose based on body weight; monitor hemoglobin and iron status. |
| 1st trimester | Limited human data; animal studies show no evidence of harm. Use only if clearly needed. |
| 2nd trimester | Limited human data; consider use if benefit outweighs risk. |
| 3rd trimester | Limited human data; may increase risk of hypertensive disorders. Use with caution. |
Clinical note
Comprehensive clinical and safety monograph for MIRCERA (MIRCERA).
| Placental transfer | Minimal transfer; molecular weight ~60 kDa and low lipid solubility likely limit placental crossing. |
| Breastfeeding | Methoxy polyethylene glycol-epoetin beta is a large molecule (~60 kDa) with limited oral bioavailability; minimal excretion into breast milk is expected. Compatible with breastfeeding based on available data. |
| Lactation Rating | L2 |
| Teratogenic Risk | Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thrombotic events in pregnant women. |
| Fetal Monitoring | Monitor hemoglobin levels weekly during initiation and periodically thereafter. Monitor blood pressure regularly. Assess for adverse thrombotic events. Fetal ultrasound if significant maternal anemia develops. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Impact on human fertility unknown. |
■ FDA Black Box Warning
WARNING: ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence. To reduce these risks, use the lowest dose sufficient to avoid red blood cell transfusion. For patients with chronic kidney disease, use only when hemoglobin is <10 g/dL and individualize dosing to maintain hemoglobin between 10-12 g/dL. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
| Serious Effects |
Uncontrolled hypertensionHistory of pure red cell aplasia (PRCA) due to erythropoiesis-stimulating agentsKnown hypersensitivity to methoxy polyethylene glycol-epoetin beta or any component of the formulation
| Precautions | Increased mortality and cardiovascular events, Increased risk of thrombotic events and vascular access thrombosis, Increased mortality in cancer patients not receiving myelosuppressive chemotherapy, Hypertension, Seizures, Pure red cell aplasia due to anti-erythropoietin antibodies, Serious allergic reactions including anaphylaxis, Tumor progression in cancer patients |
| Food/Dietary | No significant food interactions. However, maintain adequate dietary iron intake as directed. Avoid excessive alcohol, which can affect erythropoiesis. |
| Clinical Pearls | MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator (CERA) with a long half-life (approx. 130 hours). Administer intravenously or subcutaneously once every two weeks or once monthly. Monitor hemoglobin weekly until stable, then every 2-4 weeks. Target hemoglobin 10-11 g/dL; do not exceed 12 g/dL to avoid cardiovascular and thromboembolic risks. Dose reductions recommended if HB rises >1 g/dL in 2 weeks. Iron stores must be repleted (transferrin saturation ≥20%, ferritin ≥100 ng/mL). Avoid in patients with uncontrolled hypertension. |
| Patient Advice | This medication is given as an injection every 2 weeks or once a month to treat anemia due to chronic kidney disease. · Do not miss doses; if you do, contact your healthcare provider as soon as possible. · Report symptoms of high blood pressure (severe headache, blurred vision, chest pain), blood clots (pain, swelling, redness in legs; sudden shortness of breath), or allergic reactions (rash, itching, difficulty breathing). · Your hemoglobin will be monitored regularly; inform your doctor of any symptoms of anemia (fatigue, pale skin) or excess red blood cells (headache, dizziness). · Iron supplements may be needed; take them exactly as prescribed. |
Loading safety data…